Redmile Group LLC Has $25.07 Million Holdings in Xencor, Inc. (XNCR)
Redmile Group LLC lessened its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 25.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,187,494 shares of the biopharmaceutical company’s stock after selling 405,032 shares during the period. Xencor accounts for 1.5% of Redmile Group LLC’s portfolio, making the stock its 25th largest position. Redmile Group LLC owned 2.53% of Xencor worth $25,068,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in XNCR. Bank of New York Mellon Corp grew its holdings in Xencor by 15.8% during the 1st quarter. Bank of New York Mellon Corp now owns 198,988 shares of the biopharmaceutical company’s stock worth $4,759,000 after acquiring an additional 27,109 shares during the period. Parametric Portfolio Associates LLC grew its holdings in Xencor by 0.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after acquiring an additional 209 shares during the period. Prudential Financial Inc. acquired a new stake in Xencor during the 1st quarter worth $600,000. Clinton Group Inc. grew its holdings in Xencor by 4.6% during the 1st quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after acquiring an additional 700 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in Xencor by 2,826.5% during the 1st quarter. Victory Capital Management Inc. now owns 28,533 shares of the biopharmaceutical company’s stock worth $682,000 after acquiring an additional 27,558 shares during the period. 76.92% of the stock is owned by hedge funds and other institutional investors.
In related news, major shareholder John S. Stafford III purchased 27,000 shares of Xencor stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $21.13 per share, for a total transaction of $570,510.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder John S. Stafford III purchased 25,000 shares of Xencor stock in a transaction on Wednesday, August 16th. The stock was bought at an average price of $20.96 per share, with a total value of $524,000.00. The disclosure for this purchase can be found here. Insiders acquired 215,551 shares of company stock valued at $4,386,916 over the last 90 days. Corporate insiders own 4.03% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Redmile Group LLC Has $25.07 Million Holdings in Xencor, Inc. (XNCR)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/08/redmile-group-llc-has-25-07-million-holdings-in-xencor-inc-xncr.html.
Shares of Xencor, Inc. (NASDAQ XNCR) traded down 0.16% during trading on Friday, reaching $24.79. 249,273 shares of the company were exchanged. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The firm’s market cap is $1.16 billion. The stock’s 50-day moving average is $22.05 and its 200-day moving average is $22.47.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. The business had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities research analysts predict that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.
XNCR has been the subject of several research analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $36.00 price target on shares of Xencor in a report on Tuesday, August 8th. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Xencor in a report on Friday, June 16th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $28.00.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.